The US Food and Drug Administration (FDA) has granted 510(k) approval to Ethicon Endo-Surgery's ENSEAL G2 Articulating Tissue Sealer, designed to allow surgeons to take a perpendicular approach to seal vessels up to 7mm in diameter and lymphatics through a 5mm port where access is limited.
Built on the benefits of the Enseal portfolio, the articulating advanced energy device provides uniform compression, controls temperature and minimizes thermal spread with its proprietary offset electrode configuration.
Using the Proprietary I-BLADE technology, the device delivers high uniform compression for sealing vessels consistently along the length of the jaw.
Other bipolar devices do not have the Positive Temperature Coefficient technology and offset electrode configuration for minimizing energy spread into surrounding tissue, claims Ethicon Endo-Surgery.
Ethicon Endo-Surgery chief scientific officer Joe Amaral said, "ENSEAL G2 Articulating builds on an existing portfolio of advanced bipolar tissue sealers designed to give surgeons confidence and choice in surgery."
